Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
12.70
+0.03 (0.24%)
Delayed:   2:46PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 12.42 - 12.84
52 week 11.20 - 48.76
Open 12.67
Vol / Avg. 635,003.00/1.16M
Mkt cap 4.48B
P/E     -
Div/yield     -
EPS -9.42
Shares 341.19M
Beta -0.64
Inst. own 83%
May 9, 2017
Q1 2017 Valeant Pharmaceuticals International Inc Earnings Release - 9:30AM EDT - Add to calendar
May 9, 2017
Q1 2017 Valeant Pharmaceuticals International Inc Earnings Call - 8:00AM EDT - Add to calendar
May 2, 2017
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Mar 15, 2017
Valeant Pharmaceuticals International Inc at Barclays Global Healthcare Conference
Mar 2, 2017
Valeant Pharmaceuticals International Inc at Deutsche Bank Pharma One-on-One Day
Feb 28, 2017
Q4 2016 Valeant Pharmaceuticals International Inc Earnings Release
Feb 28, 2017
Q4 2016 Valeant Pharmaceuticals International Inc Earnings Call
Feb 23, 2017
Valeant Pharmaceuticals International Inc at RBC Capital Markets Healthcare Conference
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -21.31% -24.89%
Operating margin 6.26% -5.85%
EBITD margin - 41.49%
Return on average assets -4.60% -5.21%
Return on average equity -56.40% -53.16%
Employees 21,500 -
CDP Score - D

Address

Laval, 2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 61
Paul S. Herendeen Chief Financial Officer, Executive Vice President - Finance
Age: 60
Pavel Mirovsky President, General Manager, Europe
Age: 65
Christina Ackermann Executive Vice President, General Counsel
Thomas Appio Executive Vice President, President - Asia Pacific
Louis W. Yu Ph.D. Chief Quality Officer, Global Quality
Age: 65
Thomas W. Ross Sr. Lead Independent Director
Age: 65
William A. Ackman Independent Director
Age: 50
Richard U. DeSchutter Independent Director
Fredric N. Eshelman Independent Director
Age: 67